Metapharm-cro

OUR STORY

OUR  
STORY

MetaPharm Inc.  developed from close working partnerships established years prior. Many of our employees share more than 12 years of experience working together in international clinical research.

As the company is privately owned, MetaPharm Inc. enjoys unparalleled freedom that allows for independent and strategic decision making. This contributes to the outstanding stability of the company itself and creates an environment of trust, facilitating long-term collaborations and supporting your clinical development plans from set-up to completion. Furthermore, our joint responsibility enables us to work as an efficient and committed team.

Today, MetaPharm Inc. is an established full-service CRO with 2 offices and approximately 50 employees enabling access to key patient populations and investigators in both routine and rare indications.

2019 | Marketing Authorisation
Marketing authorisation granted for a contraceptive pill in the US.
2018 | Technology
new e-signature feature launched.
2017 | Marketing Authorisation
Marketing authorisation granted for an anticonvulsant for peadiadric indication in the US (epilepsy).
2016 | Marketing Authorisation
Marketing authorisation granted for a COMT inhibitor in Europe (Parkinson).
2016 | Technology
Launch of our InSIGHT application, which is a proprietary innovative clinical trial management system (CTMS).
2015 | United States of America
Opening of a new office in Pittsburgh, Pennsylvania, US, start of our expansion with our own staff to the Americas.
2013 | Technology
Launch of Metapharm's application for centralized automated electronic safety reporting (SCORIS).
2013 | Technology
Conception and start of Kaleido Metapharm development – a central portal covering several software solutions: including Safety Reporting (SCORIS) and CTMS (inSIGHT)
2013 | United Kingdom
New office opening in Manchester, UK continuing our expansion in Western Europe.
2013 | Marketing Authorisation
Marketing authorisation granted for an innovative new inhalation device for patients with asthma and/or chronic obstructive pulmonary disease (COPD) in Europe.
2013 | Extension office facilities
Further extension of International’s Mannheim headquarters in Germany.
2013 | Marketing Authorisation
Marketing authorisation granted for an anticonvulsant in the US (epilepsy).